Vanda Pharmaceuticals Inc. (VNDA) Dividend History

Company News

• Schizophrenia Clinical Trial Pipeline Insights Featuring 55+ Companies | DelveInsight

  The schizophrenia market is growing due to increased R&D activities, advancements in neurobiology and biomarkers, and ongoing clinical trials for more effective treatments. This has attracted significant investments and led to the development of innovative therapies, including novel antipsychotics and personalized medicine.

  GlobeNewswire Inc.

  Featured Companies: RVPH
• Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains?

  Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

  Zacks Investment Research
• Vanda (VNDA) Rises on Positive Data From Motion Sickness Study

  Vanda's (VNDA) tradipitant appears effective in preventing vomiting associated with motion sickness in a second phase III study. Stock rises on the news.

  Zacks Investment Research

  Featured Companies: ANIP ENTX LGND
• Zymeworks Inc. (ZYME) Reports Q1 Loss, Misses Revenue Estimates

  Zymeworks (ZYME) delivered earnings and revenue surprises of -35.48% and 44.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: ZYME
• Vanda Pharmaceuticals (VNDA) Stock Sinks As Market Gains: What You Should Know

  Vanda Pharmaceuticals (VNDA) reachead $4.56 at the closing of the latest trading day, reflecting a -1.51% change compared to its last close.

  Zacks Investment Research